Title: *Crypt-top and crypt-bottom colonic epithelial cell microRNA profiling reveals*

cell type-specific response in active and quiescent ulcerative colitis

Authors: MSc Ruta Inciuraite[1]*, PhD Rima Ramonaite[1]*, PhD Juozas Kupcinskas[1,2]*, PhD

Indre Dalgediene[3], PhD Ugne Kulokiene[1], MSc Vytautas Kiudelis[1,2], PhD Greta Varkalaite[1],

PhD Aurelija Zvirbliene[3], PhD Laimas Virginijus Jonaitis[1,2], PhD Gediminas Kiudelis[1,2], PhD

Andre Franke[4], PhD Simonas Juzenas[1,3]*, PhD Jurgita Skieceviciene[1]*

[1] Institute for Digestive Research, Academy of Medicine, Lithuanian University of Health

Sciences, A. Mickeviciaus st. 9, 44307, Kaunas, Lithuania

[2] Department of Gastroenterology, Academy of Medicine, Lithuanian University of Health

Sciences, A. Mickeviciaus st. 9, 44307, Kaunas, Lithuania

[3] Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio av. 7,

10257, Vilnius, Lithuania

[4] Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Rosalind-

Franklin St. 12, 24105, Kiel, Germany

* These authors contributed equally to this work

Correspondence: Jurgita Skieceviciene, PhD, Institute for Digestive Research, Academy of

Medicine, Lithuanian University of Health Sciences, Mickeviciaus st. 9, 44307, Kaunas,

Lithuania. Email: jurgita.skieceviciene@lsmuni.lt, phone: (370 37) 327236.

Funding: This work was supported by the Research Council of Lithuania and European

Crohn's and Colitis Organisation (grant numbers S-MIP-20-56 and ECCO Grant 2016,

respectively).

Declaration of interests: The authors declare no conflict of interest.

Summary: We present microRNA transcriptome analysis on different levels - colon tissue

and epithelial cell population - in ulcerative colitis. Results indicate cell type- and disease

stage-dependent microRNA deregulation, unveil associations with disease activity, and

putative biological role of deregulated microRNAs.

Abstract and Key Words

Background. Colonic epithelial cells form a frontline intestinal barrier and maintain its

function which deteriorates early in ulcerative colitis (UC). MicroRNAs (miRNAs) participate

in regulation of intestinal epithelial integrity and barrier permeability. However, there is a lack

of understanding about cell type-specific expression of miRNAs in UC.

Methods. Two independent cohorts composed of active and quiescent UC patients (n=74),

and healthy controls (HC; n=50) were studied. Crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$)

colonic epithelial cell populations were enriched using FACS. Small RNA-sequencing was

performed on colon biopsy and colonic epithelial cell population samples. Data processing

encompassed differential expression, gene-set enrichment analysis (GSEA) and clinical

correlation analysis.

Results. We describe differentially expressed miRNAs among active and quiescent UC

compared to HC colon tissue and propose their involvement in intestinal barrier integrity

regulation. We further focus on crypt-bottom and crypt-top colonic epithelial cells and

characterise common and cell population-specific miRNA expression in response to UC-

caused inflammation. We suggest that differentially expressed miRNAs are commonly

involved in inflammation- and intestinal barrier integrity-related processes (such as signalling

of interleukin-4 and interleukin-13), while differences between cell populations might reflect

their function, i.e., crypt-bottom cell miRNA target genes are enriched in regulation of cell

differentiation. Moreover, we show cell population-specific miRNA expression correlations

with endoscopic disease activity, i.e., let-7b-5p and let-7e-5p negatively correlates with

activity score only in the crypt-bottom cells, while miR-24-3p and miR-27a-3p positively

correlates only in the crypt-top cells.

Conclusions. Changes in miRNA expression during UC are epithelial cell type- and UC

activity-specific (including correlations with endoscopic Mayo score). Further, irrespective of

the UC stage and colonic cell population, deregulated miRNAs are potentially involved in

signalling pathways responsible for regulation of intestinal barrier integrity and permeability.

Keywords. Colon crypt-bottom (CD44$^+$) epithelial cells; colon crypt-top (CD66a$^+$) epithelial

cells; cell populations; microRNA; Ulcerative colitis.

Key Messages

What is already known? Colonic epithelium plays an important role in pathogenesis of

ulcerative colitis (UC), while microRNAs (miRNA) have been implicated in modulation of

intestinal homeostasis.

What is new here? Cell type-specific miRNA expression of colonic epithelial cells during UC

was unknown. Here, we show cell population-specific miRNA expression in response to UC-

caused inflammation in crypt-top and crypt-bottom colonic cells.

How can this study help patient care? The identified cell type-specific correlations of

miRNA expression and endoscopic Mayo score might be further evaluated in UC monitoring

and diagnostics as well as selected as targets for further therapeutics development.

Graphical abstract

Introduction

Ulcerative colitis (UC) is a chronic remitting/relapsing inflammatory disease affecting mucosa

of the lower gastrointestinal tract, including colon and rectum, and can be classified as active

or in remission (quiescent)[1]. Although development of UC is known to be a multifactorial

process involving genetic susceptibility, deregulated immune responses, epithelial barrier

defects, and environmental factors[2], the etiopathogenesis of UC remains still not fully

understood. In terms of cell populations, besides diverse types of immune cells[3,4], intestinal

epithelial cells also play a major role in the onset and course of UC[5]. Colonic epithelial cells

and their secreted products primarily form and maintain frontline intestinal barrier function

which deteriorates early during disease[6]. Colonic crypt epithelial cells such as colonocytes,

Goblet and epithelial stem cells have been shown to play an important role in UC

pathogenesis via reduced epithelial mucus secretion and/or increased barrier permeability[7].

Since one of the aims in UC management is to induce and then to maintain remission,

disentangling molecular mechanisms regulating epithelial barrier might help to artificially

modulate its permeability and retain long-lasting remission of UC.

Recent studies provide evidence for microRNAs (miRNAs) being modulators of intestinal

homeostasis by calibrating immune cell responses and regulating autophagy[8]. Furthermore,

these small non-coding RNA molecules were shown to be involved in regulation of intestinal

epithelial integrity and barrier permeability via interference with protein-coding genes

responsible for tight and adherens junctions[9], also in UC[10]. However, most of the previous

studies were either based on immortalized cell cultures or bulk tissue experiments, thus the

exact cellular context of miRNA deregulation during colonic inflammation remains elusive.

Therefore, the search for cell type specific deregulation of miRNAs in UC might uncover

novel aspects of underlying regulatory pathways and molecular targets for therapeutic

development.

Here, we report the very first study of cell type-specific miRNA expression profiles of colonic

crypt-bottom (CD44[+]) and crypt-top (CD66a[+]) cell populations in active and quiescent UC.

Initially, for hypothesis generation and cell type population selection, we apply small RNA-
seq on inflamed and non-inflamed colonic biopsies from UC patients and healthy controls.
Further, we use fluorescence-activated cell sorting (FACS) to select crypt-bottom (CD44$^+$)
and crypt-top (CD66a$^+$) cell populations from active and quiescent UC and healthy controls.
Then, by employing small RNA-seq we determine UC activity-specific, as well as cell type-
specific, signatures in miRNA expression during colonic inflammation. In addition, we
describe putative biological pathways in which the deregulated miRNAs are involved and
provide cell population-specific miRNA expression correlations with disease activity score.

Materials and Methods

Study samples

Study subject recruitment was conducted at the Department of Gastroenterology, Lithuanian University of Health Sciences (Kaunas, Lithuania) during the period of 2011-2014 (Study group I and III) and 2017-2019 (Study group II). For miRNA sequencing, colon biopsies were collected in two independent groups: the first study group contained 23 patients with active UC, 20 patients with quiescent UC and 33 healthy control individuals (HC), while the second study group was composed of 16 patients with active UC, 15 patients with quiescent UC and 17 HC individuals. Additionally, colon biopsies for qPCR-based gene expression analysis were collected in the third independent group which contained 75 patients with active UC, 50 patients with quiescent UC and 75 HC individuals. Demographic and clinical characteristics of subjects of Study groups I and II are presented in **Table 1**, Study group III – in **Supplementary Table S1**. Tissue samples of patients with active UC and quiescent UC were collected from sigmoid colon. Endoscopic activity was determined using the Mayo endoscopic subscore[1]. Quiescent UC was defined as mucosal healing (endoscopic Mayo subscore ≤ 1) with no clinical symptoms. The variables collected for the individuals of both study groups were such as age, sex, body mass index (BMI), smoking status, disease activity, localization, rectal bleeding, stool frequency, endoscopic Mayo subscore, global assessment score, full Mayo score.

All subjects with active and quiescent UC had a routine colonoscopy performed as a part of their planned examination programme. The diagnosis of UC was based on standard clinical, endoscopic, radiological, and histological criteria[11]. The control individuals included in both study groups consisted of healthy subjects who either underwent colonoscopy due to positive faecal occult blood test or were consulted on functional complaints, but had a normal colonoscopy, uninflamed mucosa during histopathological examination and no previous history of intestinal inflammation. All patients enrolled in the study were of European descent.

177 **Table 1.** Demographic and clinical characteristics of subjects

	Study group I, n=76			Study group II, n=48		
	Active UC, n=23	Quiescent UC, n=20	HC, n=33	Active UC, n=16	Quiescent UC, n=15	HC, n=17
Age						
Mean ± SD	43.9± 16.1 *	47.2 ± 13.5 *	58.5 ± 12.7 *	41.6 ± 16.3 **	57.3 ± 12.1 **	50.5 ± 16.1
Sex, n (%)						
Female	10 (43.5)	9 (45.0)	21 (73.6)	4 (25.0) ***	10 (66.7) ***	10 (58.8) ***
Full Mayo score, n (%)						
Remission	0 (0.0)	20 (100.0)	-	0 (0.0)	15 (100.0)	-
Mild	1 (4.4)	0 (0.0)	-	4 (25.0)	0 (0.0)	-
Moderate	21 (91.3)	0 (0.0)	-	11 (68.8)	0 (0.0)	-
Severe	1 (4.4)	0 (0.0)	-	1 (6.3)	0 (0.0)	-
Endoscopic Mayo subscore, n (%)						
Normal to mild	0 (0.00)	20 (100.0)	33 (100.0)	0 (0.0)	15 (100.0)	17 (100.0)
Moderate to severe	23 (100.0)	0 (0.0)	-	16 (100.0)	0 (0.0)	-
Smoking status, n (%)						
Never	8 (34.8)	11 (55.0)	23 (69.7)	9 (56.3)	10 (66.7)	12 (70.6)
Smoking	8 (34.8)	6 (30.0)	5 (15.2)	3 (18.8)	1 (6.7)	3 (17.7)
Ex-smoker	3 (13.1)	2 (10.0)	1 (5.0)	4 (25.0)	4 (26.7)	2 (11.8)
Unknown	4 (17.4)	1 (5.0)	1 (3.0)	-	-	-
BMI, kg/m^2						
Median, (range)	26.8 (18.1–56.2)	26.2 (19.7–31.5)	27.7 (19.6–39.5)	25.5 (18.0–37.2)	28.4 (19.8–32.7)	25.9 (18.9–31.9)
Unknown, n (%)	1 (4.4)	1 (5.0)	2 (6.1)	-	1 (6.7)	-

* Age differed between both active and quiescent UC groups, and HC, estimated *P* value < 0.05 (*t*-

test)

**Age differed between both active and quiescent UC groups, and HC, estimated P value < 0.05 (t-

test)

***Sex distribution differed between three groups, estimated P value < 0.05 (Pearson's chi-squared

test)

SD - Standard deviation

Colon tissue disaggregation

Colon biopsies were mechanically and enzymatically separated into single-cell suspensions.

Briefly, four to six biopsies (5–10 mg wet weight each) were washed with PBS solution

containing 50 IU/mL penicillin, 50 µg/mL streptomycin, and 0.5 mg/mL gentamicin. Biopsies

were minced into small pieces (approx. 1-2 mm^3) and incubated in 1X trypsin-EDTA solution

for 40-45 min at room temperature on an agitator to dissociate single epithelial cells from the

lamina propria. After incubation, tissue fragments were gently transferred into PBS and

shaken. The isolated cell suspension was filtered and suspended in DMEM:Ham's F-12

medium (1:1) with 15 mM HEPES (Gibco, USA) buffer for flow cytometry procedures.

Flow cytometry and fluorescence activated cell sorting

In order to minimize the loss of cell viability, fresh cell suspensions prepared shortly before

flow cytometry were used in all cell sorting experiments. Antibody staining was performed in

PBS supplemented with 1% heat-inactivated fetal bovine serum. To minimize nonspecific

binding of antibodies, cells were first incubated with Human TruStain FcX™ (Fc Receptor

Blocking Solution) (BioLegend Inc., USA) for 10 min at a concentration of 3-10 × 10^5

cells/100 µl. Cells were subsequently stained without washing with antibodies at dilutions

recommended by manufacturers. Antibodies used in this study were selected based on

previous study[12] and included: mouse anti-human CD326/EpCAM-FITC (clone VU-1D9,

RRID: AB_2534535m Life Technologies, USA), mouse anti-human CD44-APC (clone G44-

26, RRID: AB_395868, BD Biosciences, USA), mouse anti-human CD66a-PE (clone

283340, R&D Systems, USA). Cells positive for expression of non-epithelial lineage markers

were excluded by staining with mouse anti-human CD45-APC-Cy7 (clone 2D1, RRID:

AB_2566375, Biolegend Inc., USA) (see gating strategy in **Supplementary Figure S1a**).

After 20 min, stained cells were washed of excess unbound antibodies and resuspended in

PBS supplemented with 1% heat-inactivated fetal bovine serum. Flow-cytometry analysis

was performed using a CyFlow® Space cell sorter (Sysmex Partec, Germany) (see

representative plots of flow cytometry data in **Supplementary Figure S1b-d**). In cell sorting

experiments, each population of interest was sorted individually, using a protocol already

built-in within the CyFlow® Space flow cytometer software package (FloMax® 2.8), with

appropriate adjustments. Data was analysed and visualised using FlowJo™ v10.7 (BD

FlowJo, USA). Sorted cell samples were frozen and stored at -70 °C prior to total RNA

extraction.

Total RNA extraction

Total RNA extraction from colon biopsies and sorted cells was performed using standard

protocols of commercial miRNeasy Mini Kit (Qiagen, Germany) and Single Cell RNA

Purification Kit (Norgen, Canada), respectively. Total RNA concentration was evaluated by

NanoDrop2000 spectrophotometer (Thermo Scientific, USA) and Qubit 4 fluorometer

(Invitrogen, USA). Total RNA quality was assessed using Agilent 2100 Bioanalyzer (Agilent

Biotechnologies, USA).

Quantitative Reverse Transcription PCR and data analysis

To estimate the expression of *IL-4* and *IL-13* genes in colon tissue of UC patients, total RNA

from colon tissue samples was reverse transcribed using a High-Capacity cDNA Reverse

Transcription Kit (Applied Biosystems™, USA). Further, expression levels were measured

using TaqMan™ Gene Expression Assays (Assay IDs: *IL-4* Hs00174122_m1; *IL-13*

Hs00174379_m1) on the 7500 Fast Real-Time PCR System (Applied Biosystems™, USA).

The cycle threshold (C_T) values of *IL-4* and *IL-13* were normalized to the value of *GAPDH*

(Assay ID: Hs99999905_m1) reference gene. All the procedures were performed in

accordance with the manufacturer's protocol. Statistical analysis was performed using R

studio software (version 4.0.3). Data distribution was determined using the Shapiro-Wilk test,

gene expression differences were analysed the two-sided Mann-Whitney U test. The

difference between the values was considered significant when P < 0.05.

Preparation of small RNA libraries and next-generation sequencing

Small RNA libraries from tissue samples were prepared using TruSeq Small RNA Sample

Preparation Kit (Illumina, USA) with 1 µg of total RNA input per sample. Small RNA libraries

from sorted cells were prepared using NEXTFLEX Small RNA-seq Kit v3 (Bioo Scientific,

USA) with up to 50 ng of total RNA input per sample. Procedures were conducted according

to the manufacturers' protocols. The yield of sequencing libraries was assessed using the

Agilent 2200 TapeStation system (Agilent Biotechnologies, USA). Subsequently, the TruSeq

libraries were pooled with around 24 samples per lane, while the NEXTFLEX libraries were

pooled with around 16 samples per lane and then sequenced on HiSeq 4000 (Illumina, USA)

next-generation sequencing platform.

Bioinformatics and statistical analysis of small RNA-seq data

The demultiplexed raw reads (.fastq) were processed with nf-core/smrnaseq v1.0.0 best-

practise analysis pipeline using default parameters (Nextflow version v20.01.0). The pipeline

was executed within a Docker container. Briefly, depending on the small RNA-seq library

preparation kits, "illumina" or "nextflex" protocol was selected for processing of the libraries

generated from tissue and sorted cell samples, respectively. First, Trim Galore (v0.6.3) was

used to remove 3' adapter (5' - TGGAATTCTCGGGTGCCAAGG - 3' for both "illumina" and

"nextflex" protocols) sequences from the reads and additional 4 nucleotides from both 5' and

3' ends of reads (only for "nextflex" protocol). Second, to reduce computational time, the

reads with identical sequences were collapsed using seqcluster while saving the information

about the read counts. Third, Bowtie1 v1.2.2 was used to perform the alignment of collapsed

reads against mature and hairpin miRNA sequences in miRbase database v22.1. Finally,

miRNA annotation was performed using the mirTOP v0.4.23. Further, sample and miRNA

QC was performed: samples with initial read count < 1.5 IQR and number of detected

miRNAs < 1.5 IQR on $\log_2$ scale as well as non-expressed (mean raw < 1) and non-variable

miRNAs were excluded from further analysis. Subsequently, to perform differential

expression analyses of the size factor normalized counts of mature miRNAs between

samples, negative binomial generalized linear models implemented in the R package

DESeq2 were used including age (scaled and centred) and sex as covariates in the model.

The *P*-values resulting from Wald tests were corrected for false discovery rate (FDR)

according to Benjamini and Hochberg. The miRNAs with FDR < 0.05 and absolute value of

$\log_2$FC > 1 were considered to be significantly differentially expressed. A multidimensional

scaling (MDS) analysis using Euclidean distance was performed on variance stabilizing

transformation (VST) normalized miRNA count data. Additionally, Spearman's rank

correlation analysis was performed between sex- and age-adjusted normalized miRNA read

counts and endoscopic Mayo subscore. FDR < 0.05 was considered statistically significant.

Removal of sex and age effects from normalized was performed using removeBatchEffect

function from the limma R package. Statistical analyses and data processing were

performed using R version 4.0.3. Visualization of graphs was performed using the ggplot2

package.

Gene set enrichment analysis

In order to obtain putative biological functions of differentially expressed miRNAs, gene set

enrichment analysis (GSEA) was performed using Reactome pathways and GO categories.

More specifically, luciferase assay-validated miRNA-target interactions (MTIs) were obtained

from miRecords, miRTarBase and TarBase using the multiMiR package. The retrieved MTIs

were then submitted to a hypergeometric test implemented in the enrichPathway (from the

ReactomePA package) and enrichGO (from the clusterProfiler package) functions using

genes that are expressed in colon crypt-bottom (CD44[+]) and crypt-top (CD66a[+]) cells as a

background reference (defined as universe). The universe genes were obtained from single-

cell RNA-seq data of the human colon, available in GEO database with accession number

GSE116222. The pathways with FDR < 0.05 were considered to be significantly

deregulated.

Data Availability

The small RNA-seq data underlying this article will be available in Gene Expression

Omnibus (GEO) Database and will be open upon publishing with accession numbers

GSE185101 and GSE185102.

Results

Differentially expressed miRNAs in active and quiescent UC tissues are involved in regulation of inflammation-related pathways

To identify differentially expressed miRNAs and their putative regulatory processes during chronic colon inflammation, small RNA-seq was performed on inflamed (active) and non-inflamed (quiescent) colonic mucosal biopsies of UC patients and healthy controls (HC) (**Figure 1a**).

Figure 1: Small RNA-seq defines differentially expressed miRNAs involved in inflammation-associated pathways in active and quiescent UC tissues. (a) Design of the initial study phase. **(b)**

MDS plot showing the similarity structure of the miRNA transcriptomes in active (aUC) (n=23),

quiescent UC (qUC) (n=20) and HC (n=30) tissue samples based on normalized expression values.

The dots represent samples coloured by group. The centroid of ellipses corresponds to the group

mean, the shapes are defined by covariance within a given group. **(c)** Differentially expressed

miRNAs in active (aUC) (n=23) and quiescent UC (qUC) (n=20). The red colour represents

significantly (FDR < 0.05) differentially expressed miRNAs with an absolute value of $\log_2FC > 1$, while

the blue colour represents non-differentially expressed miRNAs. **(d)** Top 10 overrepresented

pathways in active (aUC) (n=23) and quiescent UC (qUC) (n=20) tissues identified by miRNA set

enrichment analysis. Dot size represents the number of miRNA-target gene count in the significantly

enriched (FDR < 0.05) Reactome pathways.

After count data normalization and quality control, 573 unique miRNAs were found to be

expressed in colon tissue samples. The overall similarity structure (based on MDS analysis;

see **Methods**) of colon miRNA transcriptomes revealed two clearly resolved clusters

corresponding to active UC and HC tissues, while the third cluster corresponding to

quiescent UC overlapped with both active UC and HC clusters, suggesting a shift of miRNA

expression from healthy to inflammatory state (**Figure 1b**). To evaluate expression of

specific miRNAs in active UC and quiescent UC, differential gene expression analysis was

performed. As expected, the most profound miRNA deregulation was observed comparing

active UC to HC or to quiescent UC (93 and 59 differentially expressed miRNAs [FDR < 0.05

and $|\log_2FC| > 1$], respectively). Interestingly, although substantially lower than in active UC,

a differential expression of miRNAs (n=32) was also observed in quiescent UC compared to

HC (**Figure 1c**; **Supplementary Table S2**). Among the differentially expressed miRNAs, a

considerable number (n=13) of molecules, including miR-106-5p, miR-125b-1-3p, miR-205-

5p and miR-3182 were deregulated in both active and quiescent UC compared to HC.

Contrarily, majority of miRNAs (n=80) including, miR-190a-5p, miR-3168, miR-378i, and

miR-223-3p were deregulated only in active UC, while miRNAs (n=19) such as miR-331-3p,

miR-409-5p, miR-4497 and miR-629-5p - only in the quiescent UC. In addition, the gradual

decrease in miR-1-3p expression was found in all pairwise comparisons (active UC vs

quiescent UC, active UC vs HC and quiescent UC vs HC; **Supplementary Table S2**). Thus,

besides shared miRNA deregulation patterns, the data also suggests unique and perhaps

non-overlapping functions of some miRNAs in active and quiescent UC.

To further determine the biological function of differentially expressed miRNAs in UC

pathogenesis, GSEA was performed for each pairwise comparison (active UC vs HC;

quiescent UC vs HC; active vs quiescent UC) using validated target genes of significantly

deregulated miRNAs and Reactome pathways (**see Methods**). The analysis indicated

similarities and differences in the over-represented pathways among the active UC,

quiescent UC and HC comparisons (**Supplementary Table S3**). Intriguingly, both active UC

and quiescent UC compared to HC had over-represented interleukin signalling-related

pathways among the top significant ones, such as "*Signaling by Interleukins*" [R-HSA-

449147] and "*Interleukin-4 and Interleukin-13 signaling*" [R-HSA-6785807] (**Figure 1d**). This

similar enrichment in the interleukin signalling-related target genes suggested that these

pathways remain dysregulated in the colonic mucosa of quiescent UC.

To assess if this deregulation can be observed not only *in silico*, but also *in vivo*, the

expression of genes coding two main cytokines IL-4 and IL-13 was evaluated in colon tissue.

The gradual increase in *IL-13* expression was observed between UC patients and HC

individuals (2.19-fold [P = 0.031] increase in quiescent UC vs. HC, 2.91-fold [P = 0.0007]

increase in active UC vs. quiescent UC, 6.38-fold [P = 2×10^{-10}] increase in active UC vs.

HC), whereas the expression of *IL-4* did not differ between the groups (**Supplementary**

Figure S2). These findings fall in concordance to GSEA results and confirm the changes in

interleukin signalling during different stages of UC.

Taken together, differential miRNA expression and GSEA analyses in UC tissues suggest

that dysregulated miRNAs are likely involved in regulation of inflammation-related pathways

and that some of the pathways, i.e., interleukin-4 and interleukin-13 signalling, remarkably,

remain dysregulated in the colonic mucosa of quiescent UC.

Sequencing of FACS-sorted colonic epithelial cells shows cell type-specific miRNA

expression during colonic inflammation

The role of interleukin-4 and interleukin-13 in mediating permeability of epithelial barrier as

well as its relation to the pathogenesis of UC has been previously described[13]. Given that

this pathway is deregulated in active UC tissues and remains deregulated in quiescent UC

(based on miRNA and mRNA expression levels in our study) and the fact that it affects

epithelial barrier function, we further decided to focus on miRNA expression in crypt-bottom

(CD44$^+$) and crypt-top (CD66a$^+$) colonic epithelial cells.

FACS was applied to enrich and select for crypt-bottom and crypt-top colonic epithelial cells

from active and quiescent UC patients and healthy controls using CD44$^+$ and CD66a$^+$

surface markers, respectively (**Supplementary Figure S1**). Analysis of FACS enriched cell

populations over single-cell analysis was chosen due to limitations of single-cell

transcriptome sequencing technology, which is not yet compatible with small RNA-seq.

Interestingly, analysis of flow cytometry showed significant (FDR < 0.05) increase in crypt-

bottom (CD44$^+$) cells in active UC compared to HC (**Figure 2a**), suggesting a potential

inflammation-stimulated cell proliferation[14,15].

Figure 2: Sequencing data reveals differentially expressed miRNAs in colonic epithelial cells of

patients with active and quiescent UC. (a) FACS of colonic epithelial cells and distribution of crypt-

top CD44⁻CD66⁺ and crypt-bottom CD44⁺CD66⁻ epithelial cell types in inflammatory (aUC) (n=16) and

non-inflammatory (qUC and HC) (n=15 and 17) colon tissues. Each dot represents a sample from the

patients of the second study group. Mean ±SD of each group is represented by vertical lines. To

compare the groups a nonparametric Mann–Whitney U test was performed, p* < 0.05. **(b)** MDS plot

showing the similarity structure of the miRNA transcriptomes in crypt-top (CD66a⁺) and crypt-bottom

(CD44⁺) colonic epithelial cell populations in active (aUC) (n=16), quiescent UC (qUC) (n=15), and in

HC (n=17) based on normalized expression values. The dots represent samples shaped by cell

population. Dot colours represent condition. The centroid of ellipses corresponds to the condition

group mean, the shapes are defined by covariance within the group. **(c, d)** Volcano plots of

differentially expressed miRNAs in crypt-top (CD66a⁺) and crypt-bottom (CD44⁺) colonic epithelial cell

populations in active (aUC) (n=16), quiescent UC (qUC) (n=15), and HC (n=17). Colours indicate

significantly (FDR < 0.05) differentially expressed miRNAs with an absolute value of $\log_2 FC > 1$

between compared groups. **(e-g)** Venn diagrams representing the numbers of commonly and uniquely

differentially expressed miRNAs in **(e)** crypt-bottom (CD44⁺) and **(f)** crypt-top (CD66a⁺) epithelial cell

populations in different UC activity, and **(g)** between crypt-bottom and crypt-top cells in the same

condition.

Using sequencing, a total number of 436 unique miRNAs were found to be expressed in

crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) epithelial cells. Although miRNA

transcriptomes of these colonic epithelial cell populations were strongly overlapping (**Figure**

2b), significant changes in expression profiles were observed within and between cell

populations in different stages of the disease (**Figure 2c and 2d**; **Supplementary Table**

S4). Initially, pairwise comparisons were performed in the same epithelial cell population to

identify UC inflammation-associated miRNAs. As in the tissue data, the number of

differentially expressed miRNAs (FDR < 0.05 and |log$_2$FC| > 1) in both colonic epithelial cell

populations were gradually increased depending on the disease activity stage, i.e., the

highest number of differentially expressed miRNAs were observed in active UC compared to

HC and to quiescent UC (**Figure 2c**). Among deregulated molecules, none of miRNAs were

commonly differentially expressed across all three comparisons (active UC vs HC; quiescent

UC vs HC; active UC vs quiescent UC) in both crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$)

colonic epithelial cells. However, six miRNAs (miR-15b-5p, miR-222-3p, miR-223-3p, miR-

194-3p, miR-3195 and miR-574-3p) were identified as commonly differentially expressed in

crypt-bottom (CD44$^+$) cells and eight miRNAs (let-7c-5p, miR-106b-3p, miR-125b-5p, miR-1-

3p, miR-1290, miR-194-3p, miR-335-5p, miR-552-3p) in crypt-top (CD66a$^+$) cells in the

active and quiescent UC when compared to HC (**Figure 2e and 2f**). Further, the response of

distinct epithelial cell populations to inflammation was determined by performing pairwise

comparisons with the separate populations of colonic epithelial cells. Twenty-four miRNAs

(such as miR-501-3p, miR-1-3p, miR-296-5p, and miR-122-5p) were identified to be

differentially expressed in active UC, nine miRNAs (such as miR-1290, miR-3168, and miR-

660-5p) in quiescent UC, and twenty-two miRNAs (such as miR-598-3p, miR-340-3p, and

miR-223-3p) - HC when compared crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) colonic

epithelial cells (**Figure 2d, Supplementary Table S4**). Importantly, function of these

miRNAs might represent a different cellular response to active inflammation in UC, e.g.,

inflammation-induced cell proliferation or apoptosis. For example, in CD44[+] cells over-

expressed miR-501-3p has been previously shown to increase cell proliferation in colorectal

cancer[16]. Notably, the vast majority of identified differentially expressed miRNAs between

distinct epithelial cell types in different stages of inflammation were found to be uniquely

dysregulated, only two commonly differentially expressed miRNAs were observed between

two comparison groups (miR-106b-3p and miR-1290 in active UC CD44[+] vs CD66a[+] and

quiescent UC CD44[+] vs CD66a[+]; miR-296-5p and miR-432-5p active UC CD44[+] vs CD66a[+]

and HC CD44[+] vs CD66a[+]) (**Figure 2g**), which suggests that even at different disease

activity stages some cell population-specific responses, in terms of miRNA expression, are

different.

Collectively, the results show some colonic cell population-specific miRNA expression

patterns in UC and at different stages of disease activity.

Aberrantly expressed miRNAs in crypt-top (CD66a[+]) and crypt-bottom (CD44[+]) colonic

epithelial cells are involved in regulation of intestinal epithelial barrier function-related

processes

To further evaluate the potential functional role of differentially expressed miRNAs in crypt-

bottom (CD44[+]) and crypt-top (CD66a[+]) colonic epithelial cells in UC pathogenesis, GSEA

was performed on validated target genes of differentially expressed miRNAs

(**Supplementary Table S5**). Similarly to the colonic tissue data (**Figure 1b**), majority of the

most overrepresented pathways in both colonic epithelial cell populations in both stages of

disease activity overlapped and included signalling pathways such as "*Signaling by*

Interleukins" (R-HSA-449147), "*Interleukin-4 and Interleukin-13 signaling*" [R-HSA-6785807],

"*Signaling by Receptor Tyrosine Kinases*" [R-HSA-9006934] (**Figure 3a**). This supports that

observations in the colon biopsy samples were mainly driven by colonic epithelial cells.

Notably, not all comparison groups in crypt-bottom (CD44[+]) cells showed uniform results.

The most overrepresented Reactome pathways in crypt-bottom (CD44[+]) cells of quiescent

UC patient group differed from those in active UC groups and exclusively included *"Signaling*

by Nuclear Receptors" (R-HSA-9006931), *"Extra-nuclear estrogen signaling"* [R-HSA-

9009391] pathways which were shown to regulate the permeability of intestinal epithelium

and thus be associated with pathogenesis of inflammatory bowel disease[17] (**Figure 3a**).

Finally, to assess which biological processes (from Gene Ontology terms) are

overrepresented in crypt-bottom (CD44$^+$) compared to crypt-top (CD66a$^+$) cells, GSEA of

deregulated miRNAs in active UC, quiescent UC, and HC groups was performed. The

results revealed the overrepresented processes between the cell populations were mainly

related to cell differentiation and motility in both active UC and HC (**Figure 3b**), suggesting

that in inflamed and healthy colon mucosa these pathways are differentially regulated

between the cell types. In addition, significant enrichment between crypt-bottom (CD44$^+$) and

crypt-top (CD66a$^+$) cells in *"epithelium migration"* [GO:0090132] and *"epithelial cell*

migration" [GO:0010631] were uniquely identified only in active UC among the most

overrepresented biological processes (**Figure 3b**). Target genes of differentially expressed

miRNAs between cell populations in the UC remission group were mainly related to cell

migration and were least different between those populations (**Figure 3b**). Noteworthy, the

GSEA results should be treated with caution, since the selection of miRNA targets

significantly affects the results[18]. However, currently, there are no methods to solve this

issue, since miRNA target prediction as well as its dosage to affect target expression are still

rather unsolved problems in the field.

Figure 3: Aberrantly expressed miRNAs of crypt-top (CD66a⁺) and crypt-bottom (CD44⁺)

colonic epithelial cells are involved in UC-related processes and reflect disease activity. Top 10

overrepresented pathways within **(a)** and between **(b)** crypt-top (CD66a⁺) and crypt-bottom (CD44⁺)

colonic epithelial cell populations during active (aUC) (n=16), quiescent UC (qUC) (n=15) and in

controls (HC) (n=17) identified by miRNA-target gene set enrichment analysis. Dot size represents the

499 number of miRNA gene-target count in the significantly enriched (FDR < 0.05) Reactome pathways

500 **(a)** and GO biological process (BP) categories **(b)**; **(c)** a heatmap showing correlations between

501 miRNA expression and endoscopic Mayo subscore in crypt-bottom (CD44$^+$) (n=48) and crypt-top

502 (CD66a$^+$) (n=48) colonic epithelial cell populations. Colour of the box represent the value of

503 Spearman's correlation coefficient (rho). Dots mark significant correlations (FDR < 0.05) in each cell

504 population.

506 To summarize, despite the significant overlap of aberrantly expressed miRNAs of both

507 colonic epithelial cell populations in regulatory signalling pathways, GSEA results reveal

508 unique involvement of particular miRNAs in UC-, inflammation- and intestinal barrier

509 integrity-related processes in different stages of disease activity and/or cell population.

511 ***Expression levels of miRNAs in crypt-top (CD66a$^+$) and crypt-bottom (CD44$^+$) colonic***

512 ***epithelial cells reflect UC activity***

513 To unveil the relation between miRNA expression levels and endoscopic Mayo subscore in

514 crypt-top (CD66a$^+$) and crypt-bottom (CD44$^+$) colonic epithelial cells, Spearman correlation

515 analysis was applied. In crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) colonic epithelial cells,

516 a number (n=34 and n=23, respectively) moderate positive (0.4 < rho < 0.7; FDR < 0.05)

517 and a few (n=6 and n=7, respectively) moderate negative (-0.7 < rho < -0.4; FDR < 0.05)

518 correlations were observed among the normalized miRNA expression levels and endoscopic

519 Mayo subscore (**Figure 3c; Supplementary Table S6; Supplementary Table S7).**

520 Although there was substantial overlapping in disease activity-associated miRNAs between

521 both colonic epithelial cell populations (29 common moderately correlating miRNAs), cell

522 population-unique correlations were also observed. The expression of 21 and 15 miRNAs

523 moderately correlated with endoscopic Mayo subscore exclusively in either crypt-bottom

524 (CD44$^+$) or crypt-top (CD66a$^+$) colonic epithelial cell population, respectively (**Figure 3c**). For

525 example, the expression of several miRNAs such as let-7b-5p, let-7e-5p and miR-141-5p

526 correlated with disease activity only in crypt-bottom (CD44$^+$) cells, while expression of

527 miRNAs such as miR-127-3p, miR-193b-5p and miR-30c-5p only in crypt-top (CD66a[+]) cells.

528 In addition, out of all correlating cell population-specific miRNAs, eight (miR-10b-5p, let-7b-

529 5p, let-7e-5p, miR-6869-5p, miR-223-3p, miR-31-5p, miR-15b-5p, miR-182-5p) were also

530 identified as differentially expressed in crypt-bottom (CD44[+]) colonic epithelial cells, and

531 seven - in crypt-top (CD66a[+]) cells (miR-194-3p, miR-196b-5p, miR-10b-5p, miR-224-5p,

532 miR-222-3p, miR-135b-5p, miR-21-5p, miR-24-3p, miR-146a-5p, miR-27a) when comparing

533 different stages of UC activity. Some of these miRNAs, such as miR-223-3p, miR-146a-5p,

534 miR-21-5p and miR-31-5p are known to be anti-inflammatory[19], which explains their

535 correlation with disease activity.

536 Generally, the results demonstrate not only common, but also colonic epithelial cell

537 population-specific correlations between miRNA expression and endoscopic disease activity

538 score.

Discussion

Although UC is a well-studied complex disease and huge efforts have been made to explore

its molecular mechanisms, the disease pathogenesis still remains largely unclear[2].

Especially, there is a substantial knowledge gap about expression patterns of regulatory

non-coding miRNA in UC in a cell type-specific context. Thus, here we present detailed

colonic epithelial cell population-specific miRNA expression profiles from active and

quiescent UC patients as well as control individuals and describe differences in miRNA

expression patterns between two distinct - crypt-bottom (CD44+) and crypt-top (CD66a+) -

cell populations. Furthermore, we also describe putative biological pathways in which the UC

deregulated miRNAs might be involved and determine associations between cell-population

specific miRNA expression and disease activity score.

Most importantly, we determined distinct responses in miRNA expression of different colonic

epithelial cell populations during UC. Our findings showed that inflammation

promoted/suppressed the expression of several miRNAs in colon crypt-bottom (CD44+) cells

(compared to crypt-top [CD66a+] cells) which might be involved in cell proliferation,

differentiation and/or permeability of intestinal barrier. For example, let-7c-5p showed

considerable ($\log_2 FC < -4$) down-regulation and miR-501-3p up-regulation ($\log_2 FC > 3.9$) in

crypt-bottom (CD44+) cells during active UC. It has previously been shown that

overexpression of let-7c-5p as well as inhibition of miR-501-3p can reduce the proliferation

of colorectal cancer cells[16,20] Thus, deregulation of these miRNAs might be related to the

relative increase of the crypt-bottom (CD44+) cells in active UC when compared to controls,

as it has been shown in our flow cytometry experiment. However, this should be confirmed in

an independent functional study employing colonic organoids. On the other hand, we

observed increased expression of miR-1-3p and decreased expression of miR-125b-5p in

crypt-bottom compared to crypt-top cells only during active UC. Both miRNAs were shown to

be involved in barrier function dysregulation, where decrease of miR-125b-5p[21] and increase

of miR-1-3p[22] was shown to disrupt epithelial barrier in colon tissue. This would suggest that

epithelial barrier is already impaired in crypt-bottom epithelial cells during active UC;

however, it remains unclear if this is a UC specific event or rather a normal cell response to

inflammation in the gut.

Furthermore, we observed that some of the differentially expressed miRNAs in crypt-bottom

(CD44⁺) and/or crypt-top (CD66a⁺) cells also correlated with endoscopic Mayo subscore.

Among these disease activity-associated miRNAs, there were well known anti-inflammatory

molecules, including miR-223-3p, miR-146a-5p, miR-21-5p and miR-31-5[19]. For example,

the expression of miR-223-3p and miR-146a-5p are known to be induced via TLR-NF-κB

pathway[23], which explains their correlation with disease activity, since the NF-κB is the

central regulator of inflammation[24]. The up-regulation of these two miRNAs has been

previously observed in biopsies of colonic mucosa in active UC[25,26]. We also determined the

positive correlation between miR-141-5p expression in crypt-bottom (CD44⁺) cells and UC

activity. It has already been shown that miR-141 is predominantly expressed in human

colonic epithelial cells[25] and takes part in pathogenesis of UC via targeting CXCL5[27]. In

addition, we identified two miRNAs belonging to let-7 family (let-7b-5p and let-7e-5p), the

expression of which negatively correlated with the endoscopic Mayo subscore exclusively in

crypt-bottom (CD44⁺) colonic epithelial cells, whereas no such association was observed in

crypt-top (CD66a⁺) cells. In the intestinal epithelium let-7b appears to be among the highest-

expressed miRNAs in let-7 group/family (**Supplementary Figure S3**). It has previously been

shown that expression of let-7 miRNAs (especially let-7e) is increased and affects

maintenance of cell differentiation[28]. Altogether, these observations suggest the relevance of

let-7 miRNAs during intestinal inflammation via maintenance of stemness of crypt-bottom

(CD44⁺) cells and thereby explain their expression correlation with disease activity,

exclusively in undifferentiated colonic epithelial cells.

Finally, we described potential involvement of differentially expressed miRNAs in regulatory

biological pathways. Our initial small RNA-seq of colonic mucosa biopsies from active and

quiescent UC compared to healthy controls, at first, revealed multiple deregulated miRNAs,

which were significantly enriched in inflammation- and intestinal epithelial barrier function-

related biological pathways. Interestingly, miRNAs enriched in interleukin biological

pathways, such as interleukin-4 and interleukin-13 signalling, were deregulated not only in

active, but also in quiescent UC, suggesting lasting derangement of this pathway in mucosa

of UC. The interleukin-4 and interleukin-13 pathway is known to differentially regulate

epithelial chloride secretion and cause epithelial barrier dysfunction[29]. It has been shown that

large amounts of interleukin-13 are produced in colon mucosa of UC patients and thereby

impair epithelial barrier function by affecting epithelial apoptosis, tight junctions, and

restitution velocity[13,30]. We also confirmed the increased expression of interleukin-13 gene

during the course of UC when analysing active and quiescent UC patient colon tissue

samples. Contrarily, some studies report decreased mucosal amounts of interleukin-13 in

active UC[31]. Nevertheless, the attempts are still being made to adapt the inhibition of

interleukin-13-based treatment to induce UC remission (e.g., clinical trials of anti-interleukin-

13 monoclonal antibodies (tralokinumab and anrukinzumab)[32] and preclinical studies of anti-

interleukin-Rα2[33]). Our findings on differentially expressed miRNA involvement in interleukin-

4 and interleukin-13 regulation even in quiescent UC as well as controversial data in the

literature led us to further focus on miRNA expression analysis in undifferentiated crypt-

bottom (CD44$^+$) and differentiated crypt-top (CD66a$^+$) colonic epithelial cells, which are

responsible for intestinal barrier integrity and permeability[7]. Similarly to the results in colonic

biopsies, both crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) epithelial cell populations

showed deregulation in miRNAs during UC, the targets of which were significantly enriched

in the interleukin-4 and interleukin-13 signalling pathway. Since interleukin-4 and interleukin-

13 cytokines are predominantly produced by immune cells[34], the expected regulatory action

of deregulated miRNAs in the colonic epithelial cells would be downstream targets of the

pathway, such as *STAT3*, *FOXO3*, *SOCS1*, etc. During active UC in both crypt-bottom

(CD44$^+$) and crypt-top (CD66a$^+$) cells, we found miR-221-3p, miR-182-6p, miR-222-3p and

miR-31-5p to be up-regulated, which are known to target *FOXO3* gene[35]. The up-regulation

of the aforementioned miRNAs, theoretically, would lead to decreased expression of the

FOXO3 gene, which was already observed in colonic mucosa of UC patients[36]. This in turn,

may lead to more severe colonic inflammation during UC[37]. Additionally, both crypt-bottom

(CD44$^+$) and crypt-top (CD66a$^+$) cells of patients with active UC had increased expression of

hsa-miR-221-3p and hsa-miR-21-5p, that target *SOCS1* gene[35]. SOCS1 is an important

regulator of interleukin-4 signalling, and its forced expression was shown to inhibit

interleukin-13 signalling in epithelial cells[38]. In addition to involvement in interleukin signalling

pathways, we also detected unique intestinal epithelial barrier function-related processes

regulated by disease stage and/or cell population-specific miRNAs. For example,

differentially expressed miRNAs, such as miR-222-3p, miR-223-3p, miR-15b-5p, in crypt-

bottom (CD44$^+$) colonic epithelial cells of quiescent UC could potentially regulate nuclear

receptors and extra-nuclear estrogen signalling pathways. These findings fall in accordance

with other studies demonstrating the importance of impairment of signal transduction via

nuclear receptors in inflammatory bowel disease, as nuclear receptors regulate essential

aspects of intestinal barrier functions such as mucus secretion, expression of tight junction

proteins and others[17]. Moreover, we observed a few aberrantly expressed miRNAs between

crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) cells in active UC, that possibly exert their

biological function through regulation of epithelial cell migration, which is known to happen

along the crypt-villus axis[39] and is increased during IBD[40].

In summary, we present a comprehensive study, which determined crypt-bottom (CD44$^+$)

and crypt-top (CD66a$^+$) colonic epithelial cell-specific miRNA deregulation in UC in cell type-

and disease stage-dependent manner. We also revealed and emphasized differences of cell

population-specific miRNA expression associations with disease activity. Furthermore, we

unveiled the potential functional role of differentially expressed miRNAs in/between two

unique crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) colonic epithelial cell populations. We

observed potential involvement of deregulated miRNAs in biological pathways associated

with maintenance of intestinal barrier function in active as well as quiescent UC, in both

epithelial cell populations. Together, these observations not only highlight regulatory

importance of miRNAs in distinct colonic epithelial cell populations during pathogenesis of

UC, but also could be applied for the development of new treatment strategies to maintain

the remission of mucosal inflammation.

Acknowledgements

This work was supported by the Research Council of Lithuania and European Crohn's and

Colitis Organisation (grant numbers S-MIP-20-56 and ECCO Grant 2016, respectively).

Ethical Considerations

The approval to perform the study was received from Kaunas Regional Biomedical Research

Ethics Committee (No. BE-2-31, 22-03-2018). All subjects have signed a written informed

consent form to participate in the study.

References

1. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N. Engl. J. Med.* 1987;317:1625–1629.

2. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. *Lancet (London, England).* 2017;389:1756–1770.

3. Montoya MM, Maul J, Singh PB, et al. A Distinct Inhibitory Function for miR-18a in Th17 Cell Differentiation. *J. Immunol.* 2017;199:559–569.

4. Jones GR, Bain CC, Fenton TM, et al. Dynamics of colon monocyte and macrophage activation during colitis. *Front. Immunol.* 2018;9.

5. Okamoto R, Watanabe M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. *J. Gastroenterol.* 2016;51:11–21.

6. Antoni L, Nuding S, Wehkamp J, et al. Intestinal barrier in inflammatory bowel disease. *World J. Gastroenterol.* 2014;20:1165–1179.

7. Nyström EEL, Martinez-Abad B, Arike L, et al. An intercrypt subpopulation of goblet cells is essential for colonic mucus barrier function. *Science.* 2021;372.

8. Zhou X, Li X, Wu M. miRNAs reshape immunity and inflammatory responses in bacterial infection. *Signal Transduct. Target. Ther.* 2018;3:1–13.

9. Cichon C, Sabharwal H, Rüter C, et al. MicroRNAs regulate tight junction proteins and modulate epithelial/endothelial barrier functions. *Tissue Barriers.* 2014;2.

10. Ye D, Guo S, Alsadi R, et al. MicroRNA regulation of intestinal epithelial tight junction permeability. *Gastroenterology.* 2011;141:1323–1333.

11. Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. *J. Crohns. Colitis.* 2017;11:649–670.

12. Dalerba P, Kalisky T, Sahoo D, et al. Single-cell dissection of transcriptional

heterogeneity in human colon tumors. *Nat. Biotechnol.* 2011;29:1120–1127.

13.   Bao K, Reinhardt RL. The differential expression of IL-4 and IL-13 and its impact on

type-2 immunity. *Cytokine.* 2015;75:25–37.

14.   Cianciulli A, Calvello R, Porro C, et al. PI3k/Akt signalling pathway plays a crucial role

in the anti-inflammatory effects of curcumin in LPS-activated microglia. *Int.*

Immunopharmacol. 2016;36:282–290.

15.   Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in

ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution.

Gastroenterology. 2005;129:550–564.

16.   Jacenik D, Zielińska M, Mokrowiecka A, et al. G protein-coupled estrogen receptor

mediates anti-inflammatory action in Crohn's disease. *Sci. Rep.* 2019;9:6749.

17.   Tahamtan A, Teymoori-Rad M, Nakstad B, et al. Anti-Inflammatory MicroRNAs and

Their Potential for Inflammatory Diseases Treatment. *Front. Immunol.* 2018;9:1377.

18.   Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth

suppressor in human colon cancer cells. *Biol. Pharm. Bull.* 2006;29:903–906.

19.   Wu F, Xing T, Gao X, et al. miR-501-3p promotes colorectal cancer progression via

activation of Wnt/β-catenin signaling. *Int. J. Oncol.* 2019;55:671–683.

20.   Du G, Yu X, Chen Y, et al. MiR-1-3p Suppresses Colorectal Cancer Cell Proliferation

and Metastasis by Inhibiting YWHAZ-Mediated Epithelial-Mesenchymal Transition.

Front. Oncol. 2021;11:264.

21.   Hübenthal M, Franke A, Lipinski S, et al. MicroRNAs and Inflammatory Bowel

Disease. In: Hedin C, Rioux JD, D'Amato M, eds. *Molecular Genetics of Inflammatory*

Bowel Disease. Cham: Springer International Publishing; 2019:203–230.

22.   Pasparakis M. IKK/NF-kappaB signaling in intestinal epithelial cells controls immune

homeostasis in the gut. *Mucosal Immunol.* 2008;1:S54–S57.

23.   Béres NJ, Szabó D, Kocsis D, et al. Role of Altered Expression of miR-146a, miR-

155, and miR-122 in Pediatric Patients with Inflammatory Bowel Disease. *Inflamm.*

Bowel Dis. 2016;22:327–335.

24.   Neudecker V, Haneklaus M, Jensen O, et al. Myeloid-derived miR-223 regulates
intestinal inflammation via repression of the NLRP3 inflammasome. *J. Exp. Med.*
2017;214:1737–1752.

25.   Huang Z, Shi T, Zhou Q, et al. miR-141 Regulates colonic leukocytic trafficking by
targeting CXCL12β during murine colitis and human Crohn's disease. *Gut.*
2014;63:1247–1257.

26.   Cai M, Chen S, Hu W. MicroRNA-141 Is Involved in Ulcerative Colitis Pathogenesis
via Aiming at CXCL5. *J. Interf. cytokine Res. Off. J. Int. Soc. Interf. Cytokine Res.*
2017;37:415–420.

27.   Chirshev E, Oberg KC, Ioffe YJ, et al. Let-7 as biomarker, prognostic indicator, and
therapy for precision medicine in cancer. *Clin. Transl. Med.* 2019;8:24.

28.   Saatian B, Rezaee F, Desando S, et al. Interleukin-4 and interleukin-13 cause barrier
dysfunction in human airway epithelial cells. *Tissue barriers.* 2013;1:e24333.

29.   Rosen MJ, Frey MR, Washington MK, et al. STAT6 activation in ulcerative colitis: a
new target for prevention of IL-13-induced colon epithelial cell dysfunction. *Inflamm.*
Bowel Dis. 2011;17:2224–2234.

30.   Kadivar K, Ruchelli ED, Markowitz JE, et al. Intestinal interleukin-13 in pediatric
inflammatory bowel disease patients. *Inflamm. Bowel Dis.* 2004;10:593–598.

31.   Giuffrida P, Caprioli F, Facciotti F, et al. The role of interleukin-13 in chronic
inflammatory intestinal disorders. *Autoimmun. Rev.* 2019;18:549–555.

32.   Karmele EP, Pasricha TS, Ramalingam TR, et al. Anti-IL-13Rα2 therapy promotes
recovery in a murine model of inflammatory bowel disease. *Mucosal Immunol.*
2019;12:1174–1186.

33.   Junttila IS. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13
Receptor Complexes. *Front. Immunol.* 2018;9:888.

34.   Ru Y, Kechris KJ, Tabakoff B, et al. The multiMiR R package and database:
integration of microRNA-target interactions along with their disease and drug
associations. *Nucleic Acids Res.* 2014;42:e133.

35.   Min M, Yang J, Yang Y-S, et al. Expression of Transcription Factor FOXO3a is
Decreased in Patients with Ulcerative Colitis. *Chin. Med. J. (Engl).* 2015;128:2759–
2763.

36.   Snoeks L, Weber CR, Wasland K, et al. Tumor suppressor FOXO3 participates in the
regulation of intestinal inflammation. *Lab. Invest.* 2009;89:1053–1062.

37.   Doran E, Choy DF, Shikotra A, et al. Reduced epithelial suppressor of cytokine
signalling 1 in severe eosinophilic asthma. *Eur. Respir. J.* 2016;48:715–725.

38.   Klepsch V, Moschen AR, Tilg H, et al. Nuclear Receptors Regulate Intestinal
Inflammation in the Context of IBD. *Front. Immunol.* 2019;10:1070.

39.   Nunes T, Bernardazzi C, Souza HS De. Cell death and inflammatory bowel diseases:
Apoptosis, necrosis, and autophagy in the intestinal epithelium. *Biomed Res. Int.*
2014;2014.

40.   Blander JM. On cell death in the intestinal epithelium and its impact on gut
homeostasis. *Curr. Opin. Gastroenterol.* 2018;34:413–419.

825